Physician profile
Asher S Imam
NPI 1376602144
$36,970.86
in general payments reported to CMS, 2019-2025
86 companies · $2,474 in 2025
The $2,474 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,039 · 2020: $12K · 2021: $7,178 · 2022: $4,391 · 2023: $3,037 · 2024: $5,306 · 2025: $2,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,327 · Travel and Lodging: $1,360 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,327.15 |
| Travel and Lodging | $1,359.76 |
| Education | $130.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12,497.01 | 2019-2022 | |
| Sk Life Science, INC. | $3,851.04 | 2020-2025 | |
| Abbvie INC. | $1,994.56 | 2019-2025 | |
| Inspire Medical Systems, INC. | $1,752.73 | 2022-2025 | Inspire |
| Abbott Laboratories | $1,440.07 | 2021-2025 | Infinity, Proclaim |
| Genentech USA, INC. | $1,329.70 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Livanova USA, INC. | $945.64 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Harmony Biosciences LLC | $878.93 | 2020-2024 | Wakix |
| Emd Serono, INC. | $816.14 | 2019-2025 | Mavenclad |
| Ucb, INC. | $806.30 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Lilly USA, LLC | $773.30 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Teva Pharmaceuticals USA, INC. | $746.39 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Biogen, INC. | $727.72 | 2019-2023 | Tysabri, Vumerity |
| Jazz Pharmaceuticals INC. | $604.96 | 2019-2024 | |
| Grifols USA, LLC | $589.81 | 2019-2025 | Gamunex-C |
Show all 86 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asher Imam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.